MOST Trial

QCGC Research staff are working colloboratively with A/Prof Paul Cohen and his team from St John of God Hospital on their national phase II MOST Trial. 34 participants hve been recruited Australia wide.

Our staff are recruiting patients who have had their chemotherapy treatment at the Royal Brisbane & Women's Hospital or North Lakes Hospital. We have been recruiting since February 2022, recruiting 15 patients so far, with more patients in the wings keen to participate.

This trial will investigate the feasibility of a novel approach to the follow-up of women with epithelial ovarian cancer after completion of surgery and chemotherapy. Patients will have nurse led follow-up with three-monthly telephone calls and will complete a patient-reported symptom assessment called the Measure of Ovarian Symptoms and Treatment concerns (MOST) questionnaire and also have a blood test for the ovarian cancer tumour marker CA125 to diagnose ovarian cancer recurrence. Many patients, particularly those living in rural and remote locations may find it difficult and costly to travel to their hospital clinic appointments. We will assess the health-related quality of life of women undergoing this novel type of follow-up compared to conventional hospital clinic-based follow-up that includes completion of the MOST.